APP and amyloidosis: Since the activation of DAPK1 function could contribute to the amyloidogenic processing of APP and the hyperphosphorylation of tau 44, DAPK1 may serve as an important therapeutic target for the simultaneous control of both amyloidosis and tauopathy in AD.